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LETTERS TO THE EDITOR
Reprinted from Australian Family Physician Vol. 35, No. 9, September 2006  665
Vertebroplasty
Dear Editor
We read with concern Guduguntla and 
Subramaniam’s (AFP May 2006) claim that 
vertebroplasty is a safe, effective and cost 
effective treatment for osteoporotic spinal 
fractures. To be able to make such a claim, 
there should be either Level I (summaries of 
well conducted RCTs), or at least Level II (at 
least one properly conducted RCT) evidence.1 
There are no completed RCTs of vertebroplasty 
and so its effectiveness including the ability 
to relieve pain, as well as both short and long 
term safety remains unproven. The promotion of 
vertebroplasty in routine care is therefore both 
premature and potentially dangerous. 
 There are many examples of seemingly 
beneficial therapies found to be ineffective or 
harmful when tested in rigorous studies.2,3 
 Nonrandomised studies may produce biased 
results for a range of reasons.4 The natural history 
of painful osteoporotic spinal fractures is to 
improve over time, often rapidly; the concept of 
‘regression to the mean’ indicates that on average 
pain is likely to have improved or regressed to an 
average, regardless of treatment; and placebo 
responses may vary 30–70% and the placebo 
response of an invasive procedure is likely to 
be accentuated.5 Furthermore, volunteers who 
agree to have the new therapy are likely to be 
different to those either who either refuse or are 
not offered it.
 Several recent studies have suggested that 
vertebroplasty may increase the risk of further 
spinal fractures, particularly in vertebrae adjacent 
to treated spinal fractures or if cement leakage 
into the adjacent disc has occurred. Trout et al6 
reported that the relative risk of having a new 
spinal fracture adjacent to a treated spinal fracture 
was 4.62 (95% CI: 4.35–4.89). Time to fracture 
was also significantly faster. In another study, 58% 
of vertebrae adjacent to discs containing cement 
subsequently fractures compared with 12% 
vertebrae not adjacent.7 In a multivariate study of 
predictors of new vertebral body fracture, cement 
leakage into the disc was the only significant 
predictor of vertebral fracture.8 Unfortunately 
none of these studies were controlled or provided 
information about osteoporosis treatment.
 The authors also state that the Medical 
Services Advisory Committee’s (MSAC) 
has recommended Medicare funding for 
vertebroplasty. We understand that this is an 
interim rebate, for limited indications. When 
further evidence becomes available, the MSAC 
recommendation will be reviewed and the 
rebate may be continued, expanded, restricted 
or withdrawn depending on the results of current 
trials. Several technology appraisals undertaken by 
international health policy makers have reported 
inadequate high quality evidence on which to 
base such a reimbursement decision.9 
 A mult icentre NHMRC funded RCT 
is  current ly  under way in  Melbourne 
(ACTRN012605000079640) to provide much 
needed evidence of the efficacy and safety of 
vertebroplasty for painful osteoporotic fractures. 
All trial participants are being followed for 2 years 
so that the question of long term safety and, in 
particular, risk of future fractures can be assessed. 
Unrestricted Medicare funding has the potential 
to seriously undermine the success of this and 
other trials by not only providing easy access to 
an unproven treatment but also by lending implicit 
support to its use. This may result in a situation 
where the true effects of this treatment may 
never be established. At present, the trial has 
recruited almost a quarter of the required sample 
and is expected to be complete within 4 years. It 
will provide pivotal evidence regarding the value 
of vertebroplasty. 
 Vertebroplasty may be a highly efficacious 
and safe treatment for painful osteoporotic spinal 
fractures but at the present time, in the absence 
of RCTs, promotion, dissemination and routine 
use of this procedure outside of the research 
setting remains unjustified. 
Rachelle Buchbinder 
Monash University, Vic 
Alexandra Barratt 
The University of Sydney, NSW
Richard H Osborne 
The University of Melbourne, Vic 
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Reply 
Dear Editor
It is 19 years since the first seven vertebroplasties 
were reported in 1987. There are only a few 
RCTs currently underway trying to provide much 
needed information on the efficacy and safety of 
vertebroplasty for painful osteoporotic fractures. 
An estimated 38 000 vertebroplasties and 16 000 
kyphoplasties have been performed in the USA,1 
which speaks for its effect in relieving pain.
 There are more than 70 published studies 
on percutaneous vertebroplasty. Although the 
scoring of individual studies quality is variable, 
the uniformity of findings does provide some 
evidence of efficacy. It is very unusual to find 
completely concordant conclusions from such 
studies in interventional radiology, but this is 
uniquely the case in percutaneous vertebroplasty. 
 There are no completed prospective randomised 
studies of vertebroplasty versus conservative 
management. The main reason for this is that at 
the clinical level vertebroplasty is so obviously 
effective in pain palliation that operators and 
referring physicians are usually quickly convinced 
of its efficiency and are then loath to randomise 
patients. There is also difficulty in randomising 
elderly patients who have severe pain to a control 
arm that often includes a sham procedure. 
 The large number of case series has shown 
that in experienced hands, the chance of a 
complication of percutaneous vertebroplasty 
that causes major illness or requires surgery is 
extremely low. The risk is higher with malignant 
